Coupled prognostic signatures for CRC

What is it about?

Stage II-III colorectal (CRC) patients with high relapse risk after surgery could potentially benefit from adjuvant chemotherapy. However, current approach for estimating relapse risk after curative surgery has limited accuracy and clinical utility. Thus, we developed a simple and effective signature to predict the post-surgery relapse risk for these patients. Fluorouracil (5-FU), often in combination with oxaliplatin or leucovorin, is the most common adjuvant chemotherapy regimen currently used as the first-line treatment for the stage II-III CRC patients. However, for those patients with high relapse risk after surgery, only parts of CRC patients could obtain benefit from 5-FU-based adjuvant chemotherapy. A great deal of CRC patients is often over-treated nowadays, which not only causes high drug costs and financial burden but also adverse effects, such as neurotoxicity. Thus, we further developed a signature to identify patients who can obtain benefit from the chemotherapy. The coupled signatures are convenient and practical in the clinical application.

Featured Image